Health And Wellness Weekly Trademark Review 5 October, 2021
You may also be interested in...
The European Commission’s proposals for solving the post-Brexit regulatory problems relating to the Northern Ireland market are welcome but they do not go far enough and risk leaving suppliers in a legal limbo, says the off-patent medicines industry.
SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.